The CDKL5 deficiency disorder market is projected to register a CAGR of 9% during the forecast period (2022 - 2027).
With the increasing COVID-19 cases worldwide, healthcare services diverted all resources toward patients suffering from COVID-19 disease. Although COVID-19 severely affects the respiratory system, it has been reported to show effects on central and peripheral systems. These included encephalopathy, inflammation, ischaemic stroke, and peripheral neurological disorders. A research study published in the National Library of Medicine in 2021 stated that the Centers for Disease Control and Prevention (CDC) had suggested that neurological comorbidities, including epilepsy, may be risk factors for COVID-19, despite a lack of evidence. However, this statement was later removed from the CDC website. One cross-sectional study investigated whether patients with active epilepsy may be at risk of COVID-19 compared to a control group. According to that study, active epilepsy would be an independent risk factor for both the incidence and mortality of COVID-19. In that study, active epilepsy was associated with a 5.1-fold greater odds ratio of mortality risk. Additionally, clinical trials on the repurposing of the epileptic drug for COVID-19 may have minimal impact on the CNS therapeutics market.
With the introduction of more sophisticated genetic testing, CDKL5 disorder is now being diagnosed in children at a relatively early age. Genetic testing prior to 2009, which sequenced the gene, would not necessarily have picked up deletions. Several individuals subsequently diagnosed with CDKL5 disorder were previously given a negative result. Therefore, a child with the phenotype who has previously tested negative, yet does not have a genetic diagnosis, should be re-tested to include deletion and duplication testing of the CDKL5 gene. As per CDKL5 Research Collaborative, there are estimated to be several thousand cases in the world, but that number frequently changes as improved genetic testing has evolved and population studies are undertaken.
The diagnosis is based on a simple blood test. More recently, some labs have used a buccal swab of the cheek. The blood or saliva swab is then sent to a special laboratory that performs the genetic test. Recently, CDKL5 testing has become widely available in epilepsy and developmental delay genetic panels, thereby allowing testing of multiple potential disease-causing genes all at the same time at a cost similar to just testing the CDKL5 gene alone. Therefore, the improved diagnosis will lead to an increased patient population, and patients will further seek treatment for the disease. In addition to this, the molecular biology of CDD is revealing opportunities in precision therapy, with phase II and III clinical trials underway or planned to assess disease-specific and disease-modifying treatments.
In the last few decades, CDD research has seen great progress, with more researchers now studying the causes, diagnosis, and treatment of CDD at many medical centers, university hospitals, and other institutions. There has been a dramatic increase in much-needed research, including ongoing clinical investigations for future therapies. Additionally, several organizations, such as the International Foundation for CDKL5 Research, CDKL5 Research Collaborative, CDKL5 alliance, CDKL5 UK, Loulou Foundation (UK), CDKL5 Alliance Francophone, along with several pharmaceutical companies, have been working in a positive direction for better treatment alternatives in the market. Also, several agents with novel mechanisms of action are also keenly being reconnoitered in ongoing clinical trials. Similarly, an initiative from several other countries is providing comprehensive and relevant health information related to various health-related problems, including CDD. Such collective and increasing awareness programs help patients to know about the disease and available safe treatment options, which are expected to drive the market growth of CDD.
The First Line Treatment Segment occupies a major share of the market over the forecast period (2022 - 2027). Seizures are clearly a big problem in CDKL5. The majority of affected children start having them within the first few weeks or months of life. Their pattern often changes and evolves with age. In many cases, seizure control proves difficult to maintain with conventional anti-epileptic drugs or other types of treatment.
Treatment for neurologic features of CDKL5 deficiency disorder is currently symptom-based and empiric rather than CDKL5 deficiency disorder-specific, though clinical trials for CDKL5 deficiency disorder are emerging. Traditional drugs are the first line of treatment for CDKL deficiency disorder. They include valproate and stiripentol. These drugs help in controlling seizures and improve cognitive function. In 2022, ganaxolone (Ztalmy) was approved to treat seizures associated with CDKL5 deficiency disorder in patients two years of age and older. This is the first treatment for seizures associated with CDKL5 deficiency disorder and the first treatment specifically for CDKL5 deficiency disorder. As per the study published in the National Library of Medicine in 2019, the most commonly used anti-seizure medications in CDD were a broad spectrum, including clobazam, valproate, topiramate, levetiracetam, and vigabatrin, and 29.6% of individuals were treated with steroids or Adrenocorticotropic hormone.
North America is expected to Hold a Significant Share in the Market and is expected to do the same in the Forecast Period.
The United States is the most affected country across the world, as there are higher numbers of patients suffering from CDKL5 deficiency disorder and higher in the North American region as the patient population is increasing compared to other countries.
North America is expected to hold a major market share in the global CDKL5 deficiency disorder market due to the rise in the prevalence of CDKL5 deficiency disorder in this region also increased awareness. The International Foundation for CDKL5 Research has eight CDKL5 Centers of Excellence in the United States - more than any other country in the world. The centers are the driving force that establishes and maintains these Centers of Excellence. According to The Orphan Disease Center, the CDKL5 gene is present on the X chromosome; most described CDKL5 patients are females (>80%), whereas boys with CDKL5 deficiency tend to show more severe symptoms. The seizures associated with CDKL5 are largely resistant to control with current anti-epileptic drugs. Approximately 1,500 patients have been diagnosed with CDKL5 deficiency globally. The prevalence is likely higher due to mis- and un-diagnosed cases.
As per the report published by Loulou Foundation International Foundation for CDKL5 Research in 2020, Current estimates of prevalence at one referral center in the United States suggest that CDKL5 deficiency may be found in about one in 75,000, representing less than 4,500 individuals with CDKL5 deficiency in the United States
Moreover, high expenditure on healthcare and genetic testing, especially in the U.S. and Canada, along with increased awareness about the disease, is fueling the growth of the overall regional Market to a large extent.
The CDKL5 deficiency disorder market is fragmented and competitive and consists of several major players. In terms of market share, a few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are Marinus Pharmaceuticals, Zogenix, REGENXBIO, Longboard Pharmaceuticals, Ovid Therapeutics, Vyant Bio, and others.
This product will be delivered within 2 business days.
With the increasing COVID-19 cases worldwide, healthcare services diverted all resources toward patients suffering from COVID-19 disease. Although COVID-19 severely affects the respiratory system, it has been reported to show effects on central and peripheral systems. These included encephalopathy, inflammation, ischaemic stroke, and peripheral neurological disorders. A research study published in the National Library of Medicine in 2021 stated that the Centers for Disease Control and Prevention (CDC) had suggested that neurological comorbidities, including epilepsy, may be risk factors for COVID-19, despite a lack of evidence. However, this statement was later removed from the CDC website. One cross-sectional study investigated whether patients with active epilepsy may be at risk of COVID-19 compared to a control group. According to that study, active epilepsy would be an independent risk factor for both the incidence and mortality of COVID-19. In that study, active epilepsy was associated with a 5.1-fold greater odds ratio of mortality risk. Additionally, clinical trials on the repurposing of the epileptic drug for COVID-19 may have minimal impact on the CNS therapeutics market.
With the introduction of more sophisticated genetic testing, CDKL5 disorder is now being diagnosed in children at a relatively early age. Genetic testing prior to 2009, which sequenced the gene, would not necessarily have picked up deletions. Several individuals subsequently diagnosed with CDKL5 disorder were previously given a negative result. Therefore, a child with the phenotype who has previously tested negative, yet does not have a genetic diagnosis, should be re-tested to include deletion and duplication testing of the CDKL5 gene. As per CDKL5 Research Collaborative, there are estimated to be several thousand cases in the world, but that number frequently changes as improved genetic testing has evolved and population studies are undertaken.
The diagnosis is based on a simple blood test. More recently, some labs have used a buccal swab of the cheek. The blood or saliva swab is then sent to a special laboratory that performs the genetic test. Recently, CDKL5 testing has become widely available in epilepsy and developmental delay genetic panels, thereby allowing testing of multiple potential disease-causing genes all at the same time at a cost similar to just testing the CDKL5 gene alone. Therefore, the improved diagnosis will lead to an increased patient population, and patients will further seek treatment for the disease. In addition to this, the molecular biology of CDD is revealing opportunities in precision therapy, with phase II and III clinical trials underway or planned to assess disease-specific and disease-modifying treatments.
In the last few decades, CDD research has seen great progress, with more researchers now studying the causes, diagnosis, and treatment of CDD at many medical centers, university hospitals, and other institutions. There has been a dramatic increase in much-needed research, including ongoing clinical investigations for future therapies. Additionally, several organizations, such as the International Foundation for CDKL5 Research, CDKL5 Research Collaborative, CDKL5 alliance, CDKL5 UK, Loulou Foundation (UK), CDKL5 Alliance Francophone, along with several pharmaceutical companies, have been working in a positive direction for better treatment alternatives in the market. Also, several agents with novel mechanisms of action are also keenly being reconnoitered in ongoing clinical trials. Similarly, an initiative from several other countries is providing comprehensive and relevant health information related to various health-related problems, including CDD. Such collective and increasing awareness programs help patients to know about the disease and available safe treatment options, which are expected to drive the market growth of CDD.
Key Market Trends
The First Line Treatment Segment is Expected to Hold a Major Market Share in the CDKL5 deficiency disorder Market
The First Line Treatment Segment occupies a major share of the market over the forecast period (2022 - 2027). Seizures are clearly a big problem in CDKL5. The majority of affected children start having them within the first few weeks or months of life. Their pattern often changes and evolves with age. In many cases, seizure control proves difficult to maintain with conventional anti-epileptic drugs or other types of treatment.
Treatment for neurologic features of CDKL5 deficiency disorder is currently symptom-based and empiric rather than CDKL5 deficiency disorder-specific, though clinical trials for CDKL5 deficiency disorder are emerging. Traditional drugs are the first line of treatment for CDKL deficiency disorder. They include valproate and stiripentol. These drugs help in controlling seizures and improve cognitive function. In 2022, ganaxolone (Ztalmy) was approved to treat seizures associated with CDKL5 deficiency disorder in patients two years of age and older. This is the first treatment for seizures associated with CDKL5 deficiency disorder and the first treatment specifically for CDKL5 deficiency disorder. As per the study published in the National Library of Medicine in 2019, the most commonly used anti-seizure medications in CDD were a broad spectrum, including clobazam, valproate, topiramate, levetiracetam, and vigabatrin, and 29.6% of individuals were treated with steroids or Adrenocorticotropic hormone.
Geography Trends
North America is expected to Hold a Significant Share in the Market and is expected to do the same in the Forecast Period.
The United States is the most affected country across the world, as there are higher numbers of patients suffering from CDKL5 deficiency disorder and higher in the North American region as the patient population is increasing compared to other countries.
North America is expected to hold a major market share in the global CDKL5 deficiency disorder market due to the rise in the prevalence of CDKL5 deficiency disorder in this region also increased awareness. The International Foundation for CDKL5 Research has eight CDKL5 Centers of Excellence in the United States - more than any other country in the world. The centers are the driving force that establishes and maintains these Centers of Excellence. According to The Orphan Disease Center, the CDKL5 gene is present on the X chromosome; most described CDKL5 patients are females (>80%), whereas boys with CDKL5 deficiency tend to show more severe symptoms. The seizures associated with CDKL5 are largely resistant to control with current anti-epileptic drugs. Approximately 1,500 patients have been diagnosed with CDKL5 deficiency globally. The prevalence is likely higher due to mis- and un-diagnosed cases.
As per the report published by Loulou Foundation International Foundation for CDKL5 Research in 2020, Current estimates of prevalence at one referral center in the United States suggest that CDKL5 deficiency may be found in about one in 75,000, representing less than 4,500 individuals with CDKL5 deficiency in the United States
Moreover, high expenditure on healthcare and genetic testing, especially in the U.S. and Canada, along with increased awareness about the disease, is fueling the growth of the overall regional Market to a large extent.
Competitive Landscape
The CDKL5 deficiency disorder market is fragmented and competitive and consists of several major players. In terms of market share, a few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are Marinus Pharmaceuticals, Zogenix, REGENXBIO, Longboard Pharmaceuticals, Ovid Therapeutics, Vyant Bio, and others.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
Table of Contents
1 INTRODUCTION
4 MARKET DYNAMICS
5 MARKET SEGMENTATION
6 COMPETITIVE LANDSCAPE
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Marinus Pharmaceuticals
- Zogenix
- REGENXBIO
- Longboard Pharmaceuticals
- Ovid Therapeutics
- Vyant Bio
Methodology
LOADING...
